Previous 10 | Next 10 |
-- Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients -- -- PROMINENT Study Failed to Show CV Risk Reduction Benefit of the Fibrate Class for Statin-Treated High-Risk Patients -- DUBL...
Summary The market is greatly overestimating the effect of higher rates and inflation on durable goods, materials and financial companies, while underestimating the impact on speculative assets. The Strategy underperformed its Russell 2000 benchmark, as positive contributions from...
Image source: The Motley Fool. Amarin (NASDAQ: AMRN) Q3 2022 Earnings Call Oct 27, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin (AMRN) Q3 2022 Earnings Call Transcript
Amarin Corp ( NASDAQ: AMRN ) posted Q3 result on Thursday that beat estimates. Q3 Non-GAAP EPS of $0.02 beats by $0.08 while revenue fell 36.7% to $89.9M, but beat estimates by $2.34M. However, the company continued to suspend 2022 revenue guidance given the un...
Amarin Corporation plc (AMRN) Q3 2022 Results Earnings Conference Call October 27, 2022, 08:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Corporate Affairs and Investor Relations Karim Mikhail - President and Chief Executive Officer Tom ...
The following slide deck was published by Amarin Corporation plc in conjunction with their 2022 Q3 earnings call. For further details see: Amarin Corporation plc 2022 Q3 - Results - Earnings Call Presentation
Amarin press release ( NASDAQ: AMRN ): Q3 Non-GAAP EPS of $0.02 beats by $0.08 . Revenue of $89.9M (-36.7% Y/Y) beats by $2.34M . As of September 30, 2022, Amarin reported aggregate cash and investments of $306.0M “In the third quarter of 2022, Amari...
-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales Mid-October As Planned – -- Obtained Positive Scientific Assessment for Reimbu...
Amarin ( NASDAQ: AMRN ) is scheduled to announce Q3 earnings results on Thursday, October 27th, before market open. The consensus EPS Estimate is -$0.06 (vs. -$0.03 last year) and the consensus Revenue Estimate is $87.49M (-38.4% Y/Y). Over the last 2 years, AMRN has...
Lars Ekman and Patrick O’Sullivan to Retire from Amarin Board at year-end New Independent Directors Bring Significant International Experience in Healthcare and Finance Seventy-five Percent New Independent Directors Appointed Over Last Twelve Months Am...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect In...
2024-05-01 11:00:14 ET Image source: The Motley Fool. Amarin Plc (NASDAQ: AMRN) Q1 2024 Earnings Call May 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript